Faruqi and Faruqui, LLP Logo
Share this page

Intra-Cellular Therapies, Inc. (ITCI)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Intra-Cellular Therapies, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Intra-Cellular Therapies, Inc. (“Intra-Cellular” or the “Company”) (NASDAQ:ITCI).

The investigation focuses on whether the Company and its executives violated federal securities laws by making misleading statements about the efficacy and safety of its schizophrenia treatment, ITI-007 (lumaterperone).

Specifically, on August 4, 2016, Intra-Cellular’s CEO Sharon Mates specified during an earnings call that “our studies to-date supports the efficacy and safety of ITI-007 for the treatment of schizophrenia.”

Then on May 1, 2017, Intra-Cellular revealed that the U.S. Food and Drug Administration had requested additional data related to nonclinical animal toxicology studies.  The agency indicated that elevated levels of drug-related metabolites that were retained in certain animal species for an extended period of time may be suggestive of a safety risk associated with long term exposure in humans.  Following this news, Intra-Cellular stock dropped on heavy volume during intraday trading on May 1, 2017.

If you invested in Intra-Cellular stock or options and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Intra-Cellular Therapies, Inc. (ITCI)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 05/01/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.